Finally, AXL has also been implicated in resistance to cetuximab treatment, a monoclonal EGFR-targeted antibody, in head and neck squamous cell carcinoma and in NSCLC [84]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.